The Claim
Intravenous administration of K1-70TM results in higher and more sustained systemic exposure compared to intramuscular administration, with a median half-life of approximately 22 days at a 150 mg dose.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
When K1-70TM is given through an IV, it stays in the bloodstream longer and at higher levels than when it is injected into muscle, with a half-life of about 22 days at a 150 mg dose.
See the scientific wording
K1-70TM administered intravenously achieves higher and more sustained systemic exposure than intramuscular administration, with a median half-life of approximately 22 days at the 150 mg dose, supporting intravenous delivery as the preferred route for future clinical development.
When K1-70TM is injected into a vein, it enters the bloodstream immediately and spreads throughout the body without being slowed down by muscle tissue. This allows more of the drug to stay in the blood for a longer time, reaching all target organs like the thyroid and eye tissues at high levels. When injected into muscle, the drug must slowly leak into the blood, which delays and reduces how much reaches the bloodstream, causing lower and shorter-lasting levels.
What the research says
1 studyWhen K1-70TM was given through an IV drip instead of a muscle shot, it stayed in the blood longer and at higher levels, which means IV works better for delivering this drug. The study found this out by testing both methods in patients.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.